Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

BOSTON, April 11, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner ...

The buying on the counter came a day after the company launched its qualified institutional placement (QIP) to raise funds up to ₹ 1,250 crore. Around 9:36 AM, Home First Finance share price was up ...

Stay informed about special deals, the latest products, events, and more from Microsoft Store. Available to United Kingdom residents. I would like information, tips and offers about Microsoft Store ...